Theravance Biopharma and Trek Therapeutics Announce

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theravance Biopharma and Trek Therapeutics Announce Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C

DUBLIN, IRELAND and CAMBRIDGE, MA--(Marketwired - Oct 27, 2015) - Theravance Biopharma, Inc. ( NASDAQ : TBPH ) ("Theravance Biopharma") and Trek Therapeutics ("TREKtx") today announced that TREKtx has initiated a Phase 2a clinical trial of TD-6450, a next-generation investigational NS5A inhibitor in development to treat patients with hepatitis C virus (HCV). Theravance Biopharma recently granted TREKtx an exclusive worldwide license for the development, manufacturing, use, marketing and sale of TD-6450 as a component in combination HCV products. Other terms of the transaction have not been disclosed.

The Phase 2a clinical trial will evaluate faldaprevir (FDV), an HCV protease inhibitor, combined with TD-6450 and ribavirin (RBV) in patients infected with HCV genotype 4. The trial is being conducted in the United States.

Mathai Mammen, M.D., Ph.D., Senior Vice President of Research and Development at Theravance Biopharma commented, "We are pleased to see the initiation of this Phase 2a clinical trial with TD-6450. This NS5A inhibitor has shown robust antiviral activity in a Phase 1 trial in patients with HCV genotype 1, as well as preclinical potency against both wild type HCV and resistance-associated variants. We believe that its antiviral activity, in combination with other antivirals, may help improve cure rates and/or reduce treatment times for appropriate patients. We are especially pleased to collaborate with TREKtx and support their commitment to delivering novel and accessible combination HCV treatments to patients worldwide."

"We are very excited about dosing our first genotype 4 patients in this combination study. If safety and efficacy are demonstrated, the goal is to initiate clinical trials in Egypt next year, where the need is enormous," said Dr. Robert Hindes, Chief Medical Officer of Trek Therapeutics.

About TD-6450

Theravance Biopharma discovered TD-6450, a multivalent NS5A inhibitor designed to have improved antiviral activity against genotype 1 resistance-associated variants (RAV) resistant to first generation NS5A inhibitors. TD-6450 has successfully completed Phase 1 studies in both healthy volunteers and HCV patients.

About Faldaprevir Faldaprevir is a protease inhibitor that TREKtx acquired from Boehringer Ingelheim. FDV has completed Phase 3 studies in combination with pegylated interferon and RBV.

About HCV Hepatitis C is an infectious disease of the liver. Of people infected, 55 to 85 percent will develop chronic infection, and 75 percent of those with chronic infection will develop chronic liver disease.

The U.S. Centers for Disease Control and Prevention estimates 2.7 million individuals in the United States have active hepatitis C virus (HCV) infection, most of whom are "baby boomers." In the United States, chronic HCV infection is the leading cause of cirrhosis and liver cancer and the most common reason for liver transplantation. Worldwide, more than 135 million people have chronic HCV infection and most are undiagnosed.

About Trek Therapeutics TREKtx is a private, clinical stage public benefit corporation developing treatments for serious infections. Its mission is to profitably develop affordable and accessible medicines to treat infectious diseases and to commercialize them for global populations. The company's founders collectively participated in the development of seven approved antiviral drugs.

About Theravance Biopharma The mission of Theravance Biopharma ( NASDAQ : TBPH ) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV ® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for COPD. Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, we have an economic interest in future payments that may be made by GlaxoSmithKline plc pursuant to its agreements with Theravance, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium and vilanterol (the "Closed Triple").

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients. For more information, please visit www.theravance.com .

THERAVANCE ® , the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE ® and VIBATIV ® are registered trademarks of the Theravance Biopharma group of companies.

This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company's strategies, plans and objectives, the Company's regulatory strategies and timing and results of clinical studies, the potential benefits and mechanisms of action of the Company's product and product candidates and the Company's expectations for product candidates through development and commercialization. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of the press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's product candidates are unsafe or ineffective, the feasibility of undertaking future clinical trials for our product candidates based on FDA policies and feedback, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with third parties to discover, develop and commercialize product and product candidates and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate expertise and supporting infrastructure. Other risks affecting Theravance Biopharma are described under the heading "Risk Factors" contained in Theravance Biopharma's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 13, 2015. In addition to the risks described above and in Theravance Biopharma's other filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

Contact Information: Theravance Biopharma Renee Gala Chief Financial Officer 650-808-4045 investor.relations@theravance.com Tim Brons Vida Strategic Partners (media) 646-319-8981 tbrons@vidasp.com Trek Therapeutics Jane A. Kramer Fiksu Communications 781-799-9524 kramerj@fiksucomms.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 229

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 182

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 187

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Withdraw from Firms Vulnerable to AI Disruption

Updated Category News Views 397

The Growing Concern Over AI Disruption In recent times, there has been increasing unease among investors related to how artificial intelligence (AI) could potentially disrupt numerous industries. This anxiety has led to significant withdrawals from companies viewed as susceptible to these technological advancements. Identifying At-Risk Companies Firms such as Adobe Inc....

Continue Reading
Community Impact: Sunrise Maids Enhances Lives in Katy Area

Updated Category News Views 152

Sunrise Maids: Committed to Community Enrichment Sunrise Maids is not just another cleaning service; it embodies the spirit of giving back in Katy with its exceptional maid services. This locally operated company is well-known for its unwavering commitment to maintaining clean and healthy living spaces. But what sets Sunrise Maids apart is their strong dedication to...

Continue Reading
Air France-KLM Launches New Liquidity Contract with Rothschild

Updated Category News Views 188

Introduction of a New Liquidity Contract Air France-KLM is excited to announce its latest initiative to enhance market performance through a new liquidity contract. This partnership with Rothschild Martin Maurel is designed to fortify the trading environment for its shares, aligning with regulatory frameworks and practices. Details of the Liquidity Agreement The liquidity...

Continue Reading
Valeo's H1 2025 Performance: Insights and Financial Highlights

Updated Category News Views 499

Overview of Valeo's H1 2025 Financial Results Valeo has exhibited a notable improvement in its profitability metrics during the first half of 2025. The company's operating margin reached 4.5%, while their free cash flow stood at an impressive 252 million euros. This performance aligns well with Valeo's overall goals for profitability and cash generation for the year....

Continue Reading
Chinese Financial Landscape Shifts as Central Bank Takes Action

Updated Category News Views 90

Chinese Stocks Surge After Central Bank's Stimulus Measures Chinese stocks saw a notable increase after an unexpected announcement from the central bank, which introduced vital monetary stimulus measures. This decisive action is designed to revive the slowing economy and restore confidence among investors. Monetary Easing: A Comprehensive Approach The central bank...

Continue Reading